Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)

Clinical trial NCT04138381 · UNKNOWN

Trial details

NCT number: NCT04138381
Sponsor: Grupo Espanol de Investigacion en Sarcomas
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Maximum Tolerated Dose GIST Metastatic Adult Soft Tissue Sarcoma Drug Toxicity Drug Use

Start date: 2019-08-16
Primary completion: 2023-04-16
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.